Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717441 | 0.80 | ALOX5 (0.54) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL4603703 | 0.80 | ALOX5 (0.48) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL5690322 | 0.78 | PKM (0.54) | ALOX5MAPTPKMCYP2A6HDAC3 | |
| SCHEMBL3742330 | 0.78 | ALOX5 (0.41) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL13041056 | 0.78 | ALOX5 (0.41) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL4285747 | 0.77 | CA2 (0.51) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL24406257 | 0.77 | ALOX5 (0.55) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL2977121 | 0.77 | ALOX5 (0.51) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL1105793 | 0.77 | ALOX5 (0.55) | ALOX5MAPTPKMSLC6A4SLC6A2 | |
| SCHEMBL1095514 | 0.77 | ALOX5 (0.55) | ALOX5MAPTPKMSLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | PLIVA D.D. (HR) | 2008-04-17 | — | — | US | disclosed |
| US-7345048-B2 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | PLIVA D.D. (HR) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | ALOX5 542/4885MAPT 4636/4885PKM 3806/4885 |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | AAAS, ALAD, NAALAD2 | ALOX5 1696/4885MAPT 4054/4885PKM 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.